{
  "docId": "019de070-9f9d-7718-acb6-17a3db6270ac",
  "docSlug": "7a58434f86a94bb0eba92fad9f688c31",
  "documentTitle": "23andMe | SPAC Presentation Deck | 47 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 47,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Includes a testimonial from Dr. Hal Barron of GSK.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-9f9d-7718-acb6-17a3db6270ac/31",
  "deckHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac",
  "deckJsonHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac.json",
  "deckAnchorHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "And some GSK unilateral programs.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b4c5b4f-0621-4107-9e5c-5dd4d63d921b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.6
      },
      "kind": "list",
      "text": "Oncology, Immunology, Cardiovascular, Metabolic Disease, Neurology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb8ef5ed-ea34-44c0-a09a-cbd133d0f973",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.2,
        "y": 0.25
      },
      "kind": "metric",
      "text": "50/50 shared costs and profits",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06990b2e-d33c-45ad-83bd-69d9a867092e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.6,
        "y": 0.1
      },
      "kind": "metric",
      "text": "30+ joint profit sharing programs",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eb2f4d8-d135-480b-9b1c-bb9d6444f3ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "metric",
      "text": "Access to GSK technology and platforms",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5377591-df2c-4fee-9803-8926418f7367",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "metric",
      "text": "$300M equity investment",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e45ef710-db9d-490d-a054-cab8620cd9e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "quote",
      "text": "Our work with 23andMe is exceeding expectations and helping us advance a new way of thinking about drug discovery... Dr. Hal Barron, Chief Scientific Officer & President R&D, GSK (2021)",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1339848b-54c5-4704-85d9-20d55bc7e2f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Strategic Collaboration With gsk",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6db00b6d-c69b-462b-b9bd-c528597feb3b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 47,
      "from": 31,
      "beatId": "c6e32088-5ffd-4801-8f4d-73b03f070b9a",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Ultimate Achievement",
      "beatSlug": "rags-to-riches-ultimate-achievement",
      "evidence": "The deck concludes with 23andMe's financials, growth prospects, and transaction overview",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 31,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "948c0ef0-9704-4173-be05-25230dbef10f",
      "evidence": "The deck presents 23andMe's lead CD96 program and pipeline across multiple therapeutic areas",
      "position": 2,
      "objective": "The potential for 23andMe's therapeutics discovery efforts",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}